Takeda to invest €100m at Grange Castle facility
TAKEDA Pharmaceutical plan to spend up to €100 million on a new manufacturing plant in Grange Castle Business Park that will employ up to 100 people.
A subsidiary of Japanese global research-based pharmaceutical company, Takeda aims to build a 3,000 sq.m, two-storey plant beside an existing facility at Grange Castle.
The pharma company owns 19 hectares of land at Grange Castle, of which about half is developed.
News of the expansion comes less than a year after Takeda announced a €40 million extension at Grange Castle – a plant which is expected to become operational by late 2018 and create 40 jobs.
The largest pharmaceutical firm in Asia, Takeda first opened an Irish base in Bray in 1997, and employ over 400 people in Ireland, with more than 30,000 employees worldwide.
In 2002, the firm opened the first Takeda pharma plant outside Japan in Grange Castle, a move which represented a key strategic addition to the group’s global production network.
Meanwhile, Takeda Products Ireland is based in Citywest, to market the company’s products in the Republic of Ireland.
The extension announced last year was to facilitate the manufacture of Takeda’s blood-cell cancer drug Ninlaro for global markets.
Billed by the firm as a flagship investment, Ninlaro was approved in November 2015 by the US Food and Drug Administration and also launched in Japan the following year.
It is a first of its kind once-weekly oral proteasome inhibitor for the treatment of patients with multiple myeloma.
Takeda had revenues of over €13 billion last year and is ranked in the top 15 drug companies in the world.
